Author

Taku Kobayashi

CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Taku Kobayashi  et al.

EARLY REDUCTION OF BOWEL WALL THICKNESS BY TRANSPERINEAL ULTRASONOGRAPHY PREDICTS BIOLOGICS-INDUCED DEEP REMISSION IN ULCERATIVE COLITIS
EARLY REDUCTION OF BOWEL WALL THICKNESS BY TRANSPERINEAL ULTRASONOGRAPHY PREDICTS BIOLOGICS-INDUCED DEEP REMISSION IN ULCERATIVE COLITIS

Taku Kobayashi  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

Taku Kobayashi  et al.

ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS

Taku Kobayashi  et al.

EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS
EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Taku Kobayashi  et al.

EVALUATION OF A COMPUTATIONAL PLATFORM FOR PREDICTING TEMPORAL PROGRESSION OF MUCOSAL DAMAGE AND HEALING IN PATIENTS WITH CROHN’S DISEASE
EVALUATION OF A COMPUTATIONAL PLATFORM FOR PREDICTING TEMPORAL PROGRESSION OF MUCOSAL DAMAGE AND HEALING IN PATIENTS WITH CROHN’S DISEASE

Taku Kobayashi  et al.

PROLONGED BENEFIT OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS IN SELECTION
PROLONGED BENEFIT OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS IN SELECTION

Taku Kobayashi  et al.

TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY
TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Taku Kobayashi  et al.

EARLY REDUCTION OF BOWEL WALL THICKNESS BY TRANSPERINEAL ULTRASONOGRAPHY PREDICTS BIOLOGICS-INDUCED HISTO-ENDOSCOPIC MUCOSAL IMPROVEMENT IN ULCERATIVE COLITIS
EARLY REDUCTION OF BOWEL WALL THICKNESS BY TRANSPERINEAL ULTRASONOGRAPHY PREDICTS BIOLOGICS-INDUCED HISTO-ENDOSCOPIC MUCOSAL IMPROVEMENT IN ULCERATIVE COLITIS

Taku Kobayashi  et al.

THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB

Taku Kobayashi  et al.

TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY
TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

Taku Kobayashi  et al.

EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS

Taku Kobayashi  et al.

Item 1 - 12 / 12
1